Kailera Therapeutics shares surged 62.5% in their Nasdaq debut after raising $625 million in a U.S. IPO priced at the top end of its range....

The starting dose price is cut by 55% to Rs 3,999 per month (four weekly doses). The innovator semaglutide is available in a once-weekly pe...

Glenmark Pharmaceuticals is set to launch affordable versions of the popular anti-diabetes and obesity drug semaglutide. This move escalate...

Novo Nordisk has slashed Wegovy prices in India by nearly 40 percent. This move has dramatically increased sales volume by 70 percent in No...

Eli Lilly stock today: Eli Lilly achieved a historic milestone, briefly touching a $1 trillion market cap. This success is driven by strong...

In June, Novo Nordisk launched Wegovy (semaglutide) injections in five dosing strengths (0.25, 0.5, 1, 1.7 and 2.4 mg). However, the compan...

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide under the brand n...

Pfizer has agreed to acquire obesity drug developer Metsera for up to $86.25 a share, surpassing Novo Nordisk's final offer. This move mark...

Metsera has accepted Pfizer's $10 billion acquisition offer. This ends a bidding war with rival Novo Nordisk. Pfizer will pay $86.25 per sh...

Pfizer is increasing its offer for Metsera. This comes after a judge rejected Pfizer's attempt to stop rival Novo Nordisk's bid. Pfizer's d...

A fierce bidding war is underway for Metsera, an obesity drug developer. Novo Nordisk has made a $10 billion offer, which Metsera considers...

Pfizer sued Metsera and Novo Nordisk, alleging Metsera breached its merger agreement by deeming Novo's $8.5 billion bid superior. Pfizer se...

European shares tumbled on Friday, on course for their biggest drop in six weeks, as renewed concerns about the health of U.S. regional ban...

Lilly's orforglipron is designed to mimic the appetite-suppressing GLP-1 hormone targeted by the company's blockbuster injection tirzepatid...

European shares were little changed in early trade on Monday, with investors on the watch for Ukraine and European leaders' meeting with U....

Novo Holdings is the latest challenger in a hotly contested bidding process for Healthium, 99.8% owned by Apax Partners. Buyout funds KKR, ...

AstraZeneca announced its acquisition of Amolyt Pharma, a company focused on endocrine diseases, for $1.05 billion in cash. This move aims ...